Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
n=17), compared to the ~0.4% increase in HbA1c seen post-GLP-1 discontinuation in the STEP-1 trial extension 2 of GLP-1 withdrawal
After 56 weeks: Placebo group lost 1.6% of body weight Starting dose (3.75/23 mg) group lost 5.1% of body weight Top dose (15/92 mg) group lost 10.9% of body weight Beyond weight loss, the CONQUER trial showed significant improvements in blood pressure, waist circumference, lipid profiles, glycemic parameters, and inflammatory biomarkers compared to placebo
For those with type 2 diabetes, Semaglutide can also help reduce the risk of cardiovascular events
LIRA KO by 2-factor ANOVA
Key safety information in the Prescribing Information includes: Use in patients with prior pancreatitis: Tirzepatide has not been studied in patients with a history of pancreatitis
US$ 25.21
US$ 25.86
US$ 20.48
US$ 21.06
US$ 21.08
